BCTX
BriaCell Therapeutics Corp.
$3.70
+0.21 (+6.02%)
At close · Jul 8
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$32.19M
Shares
8,699,787
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.70
Open$3.51
Day$3.43–3.82
52W$2.60–30.00
Avg vol 30d198K
Short int377K · 4.3% float · 1.5d
Short vol74%
Last earningsOct 28, 2022
DataJan 2020–Jul 2026
Filing10-Q · Jun 9
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
+7%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
4%
near low
Momentum
relative strength
1-month return
+20%
trailing
6-month return
−66%
trailing
YTD return
−48%
this year
Relative strength
−74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.33% of float · ▼ -56.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — 13F breadth
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
−42%
Y/Y
Free cash flow
$-28.6M
Valuation
P/E 1.6
below peers
Balance sheet
$10.5M
net cash
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ4-26 quarter ends
~Jul 31, 2026
Est
filed Jun 9, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.33% of float · ▼ -56.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $3
Now $4 · 4%
52-wk high $30
vs 200-day avg -43%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCTX
this stock
BriaCell Therapeutics Corp.
|
$32.19M | -48.0% | — | 1.6 | 4.3% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
16
- % held
- 4.4%
- Net QoQ
- +377.1K sh
- Top holder
- Cable Car Capital, LP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCTX | +14.2% | +19.7% | -66.1% | +14.2% | -48.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +14.4% | +18.9% | -73.6% | +14.4% | -57.3% |